Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

To address the recent explosion in the number of effective therapies for atopic dermatitis, one dermatologist proposes a relatively simple way of organizing choices.

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic ...

Experts discuss the challenges of managing atopic dermatitis in real-world clinical practice, highlighting access barriers due to insurance disparities, the need for creative solutions to provide ...

Dupilumab demonstrated robust efficacy, durable benefits, and a favorable safety profile in children with moderate-to-severe ...

Mild-to-moderate Atopic Dermatitis (AD) may be adequately treated with a combination of trigger avoidance, moisturizers, topical corticosteroids, calcineurin inhibitors and/or crisaborole. However, ...

Up to 15 percent of children and five percent of adults are affected by the chronic inflammatory skin disease atopic dermatitis. Despite advanced therapy measures, the severe itching and eczema, ...

There are a number of misconceptions about the use of biologic medications for atopic dermatitis. Find out what experts say ...

Atopic dermatitis, the most common form of eczema, is a widespread skin condition known for causing dry, itchy and inflamed skin. It affects 15% to 20% of children and 8% to 10% of adults. The ...

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?